DUBLIN, May 24, 2017 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
will host a webcast to discuss data to be presented on JZP-110 and
Xyrem® (sodium oxybate) oral solution during the Associated
Professional Sleep Societies (APSS) Annual Meeting taking place
from June 3-7, 2017 in Boston, MA.
The live webcast will begin at 7:00 p.m.
EDT on June 6, 2017. The
webcast may be accessed from the Investors section of the Jazz
Pharmaceuticals website at www.jazzpharmaceuticals.com. Please
connect to the website prior to the start of the presentation to
ensure adequate time for any software downloads that may be
necessary to listen to the webcast.
An audio archive of the webcast will be available for at least
one week following the presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is an international biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing meaningful products that address unmet medical
needs. The company has a diverse portfolio of products and product
candidates, with a focus in the areas of sleep and
hematology/oncology. In these areas, Jazz Pharmaceuticals
markets Xyrem® (sodium oxybate) oral solution, Erwinaze®
(asparaginase Erwinia chrysanthemi) and Defitelio®
(defibrotide sodium) in the U.S. and markets Erwinase® and
Defitelio® (defibrotide) in countries outside the U.S. For
more information, please visit www.jazzpharmaceuticals.com.
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg